Diabetes - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols CTNNB1 and MEG3	Name 1 catenin beta 1	Name2 maternally expressed 3	Pathway 1 Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade TCF dependent signaling in response to WNT Formation of the beta-catenin:TCF transactivating complex Formation of the beta-catenin:TCF transactivating complex LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Apoptotic cleavage of cell adhesion proteins Deactivation of the beta-catenin transactivating complex Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Ca2+ pathway Adherens junctions interactions Binding of TCF/LEF:CTNNB1 to target gene promoters Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability Myogenesis Myogenesis Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated RHO GTPases activate IQGAPs Transcriptional Regulation by VENTX InlA-mediated entry of Listeria monocytogenes into host cells RUNX3 regulates WNT signaling Cardiogenesis Germ layer formation at gastrulation Regulation of CDH11 function Regulation of CDH11 function Regulation of CDH19 Expression and Function Regulation of CDH1 Function Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Formation of paraxial mesoderm Formation of axial mesoderm Formation of definitive endoderm Somitogenesis Regulation of MITF-M-dependent genes involved in pigmentation Regulation of MITF-M-dependent genes involved in cell cycle and proliferation Formation of the nephric duct CDH11 homotypic and heterotypic interactions Specification of the neural plate border High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Transcriptional and post-translational regulation of MITF-M expression and activity Regulation of PD-L1(CD274) transcription	Pathway 2	Drugs 1 Urea	Drugs 2	Diseases 1 Pilomatricoma; Epithelioma calcificans of Malherbe Gastric cancer Hepatocellular carcinoma Thyroid cancer Colorectal cancer Endometrial Cancer	Diseases 2
Novel Novel	Symbols CTNNB1 and PFKFB3	Name 1 catenin beta 1	Name2 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Pathway 1 Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade TCF dependent signaling in response to WNT Formation of the beta-catenin:TCF transactivating complex Formation of the beta-catenin:TCF transactivating complex LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Apoptotic cleavage of cell adhesion proteins Deactivation of the beta-catenin transactivating complex Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Ca2+ pathway Adherens junctions interactions Binding of TCF/LEF:CTNNB1 to target gene promoters Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability Myogenesis Myogenesis Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated RHO GTPases activate IQGAPs Transcriptional Regulation by VENTX InlA-mediated entry of Listeria monocytogenes into host cells RUNX3 regulates WNT signaling Cardiogenesis Germ layer formation at gastrulation Regulation of CDH11 function Regulation of CDH11 function Regulation of CDH19 Expression and Function Regulation of CDH1 Function Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Formation of paraxial mesoderm Formation of axial mesoderm Formation of definitive endoderm Somitogenesis Regulation of MITF-M-dependent genes involved in pigmentation Regulation of MITF-M-dependent genes involved in cell cycle and proliferation Formation of the nephric duct CDH11 homotypic and heterotypic interactions Specification of the neural plate border High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Transcriptional and post-translational regulation of MITF-M expression and activity Regulation of PD-L1(CD274) transcription	Pathway 2 Regulation of glycolysis by fructose 2,6-bisphosphate metabolism	Drugs 1 Urea	Drugs 2	Diseases 1 Pilomatricoma; Epithelioma calcificans of Malherbe Gastric cancer Hepatocellular carcinoma Thyroid cancer Colorectal cancer Endometrial Cancer	Diseases 2
Novel Novel	Symbols CTNNB1 and PTPRM	Name 1 catenin beta 1	Name2 protein tyrosine phosphatase receptor type M	Pathway 1 Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade TCF dependent signaling in response to WNT Formation of the beta-catenin:TCF transactivating complex Formation of the beta-catenin:TCF transactivating complex LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Apoptotic cleavage of cell adhesion proteins Deactivation of the beta-catenin transactivating complex Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Ca2+ pathway Adherens junctions interactions Binding of TCF/LEF:CTNNB1 to target gene promoters Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability Myogenesis Myogenesis Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated RHO GTPases activate IQGAPs Transcriptional Regulation by VENTX InlA-mediated entry of Listeria monocytogenes into host cells RUNX3 regulates WNT signaling Cardiogenesis Germ layer formation at gastrulation Regulation of CDH11 function Regulation of CDH11 function Regulation of CDH19 Expression and Function Regulation of CDH1 Function Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Formation of paraxial mesoderm Formation of axial mesoderm Formation of definitive endoderm Somitogenesis Regulation of MITF-M-dependent genes involved in pigmentation Regulation of MITF-M-dependent genes involved in cell cycle and proliferation Formation of the nephric duct CDH11 homotypic and heterotypic interactions Specification of the neural plate border High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Transcriptional and post-translational regulation of MITF-M expression and activity Regulation of PD-L1(CD274) transcription	Pathway 2	Drugs 1 Urea	Drugs 2	Diseases 1 Pilomatricoma; Epithelioma calcificans of Malherbe Gastric cancer Hepatocellular carcinoma Thyroid cancer Colorectal cancer Endometrial Cancer	Diseases 2
Novel Novel	Symbols CTNNB1 and SALL1	Name 1 catenin beta 1	Name2 spalt like transcription factor 1	Pathway 1 Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade TCF dependent signaling in response to WNT Formation of the beta-catenin:TCF transactivating complex Formation of the beta-catenin:TCF transactivating complex LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Apoptotic cleavage of cell adhesion proteins Deactivation of the beta-catenin transactivating complex Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Ca2+ pathway Adherens junctions interactions Binding of TCF/LEF:CTNNB1 to target gene promoters Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability Myogenesis Myogenesis Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated RHO GTPases activate IQGAPs Transcriptional Regulation by VENTX InlA-mediated entry of Listeria monocytogenes into host cells RUNX3 regulates WNT signaling Cardiogenesis Germ layer formation at gastrulation Regulation of CDH11 function Regulation of CDH11 function Regulation of CDH19 Expression and Function Regulation of CDH1 Function Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Formation of paraxial mesoderm Formation of axial mesoderm Formation of definitive endoderm Somitogenesis Regulation of MITF-M-dependent genes involved in pigmentation Regulation of MITF-M-dependent genes involved in cell cycle and proliferation Formation of the nephric duct CDH11 homotypic and heterotypic interactions Specification of the neural plate border High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Transcriptional and post-translational regulation of MITF-M expression and activity Regulation of PD-L1(CD274) transcription	Pathway 2 POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation Formation of the ureteric bud	Drugs 1 Urea	Drugs 2	Diseases 1 Pilomatricoma; Epithelioma calcificans of Malherbe Gastric cancer Hepatocellular carcinoma Thyroid cancer Colorectal cancer Endometrial Cancer	Diseases 2 Townes-Brocks syndrome
Novel Novel	Symbols CUX1 and EHMT2	Name 1 cut like homeobox 1	Name2 euchromatic histone lysine methyltransferase 2	Pathway 1 Signaling by cytosolic FGFR1 fusion mutants Signaling by FGFR1 in disease Intra-Golgi traffic	Pathway 2 Senescence-Associated Secretory Phenotype (SASP) PKMTs methylate histone lysines ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression Regulation of TP53 Activity through Methylation RNA Polymerase I Transcription Initiation Transcriptional Regulation by VENTX Transcriptional Regulation by E2F6 Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CDKN1A and CSAD	Name 1 cyclin dependent kinase inhibitor 1A	Name2 cysteine sulfinic acid decarboxylase	Pathway 1 SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint TFAP2 (AP-2) family regulates transcription of cell cycle factors Transcriptional regulation by RUNX2 RUNX3 regulates CDKN1A transcription Neddylation Transcriptional regulation of granulopoiesis FOXO-mediated transcription of cell cycle genes Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2 Degradation of cysteine and homocysteine	Drugs 1 Valproic acid Arsenic trioxide	Drugs 2 Pyridoxal phosphate Cysteine	Diseases 1 Cervical cancer	Diseases 2
Novel Novel	Symbols CDKN1A and F13A1	Name 1 cyclin dependent kinase inhibitor 1A	Name2 coagulation factor XIII A chain	Pathway 1 SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint TFAP2 (AP-2) family regulates transcription of cell cycle factors Transcriptional regulation by RUNX2 RUNX3 regulates CDKN1A transcription Neddylation Transcriptional regulation of granulopoiesis FOXO-mediated transcription of cell cycle genes Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2 Platelet degranulation Common Pathway of Fibrin Clot Formation Interleukin-4 and Interleukin-13 signaling	Drugs 1 Valproic acid Arsenic trioxide	Drugs 2 N-Acetyl-Serine Thrombin Prothrombin Human thrombin Anti-inhibitor coagulant complex	Diseases 1 Cervical cancer	Diseases 2 Factor XIII deficiency
Novel Novel	Symbols CDKN1A and PDHB	Name 1 cyclin dependent kinase inhibitor 1A	Name2 pyruvate dehydrogenase E1 subunit beta	Pathway 1 SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint TFAP2 (AP-2) family regulates transcription of cell cycle factors Transcriptional regulation by RUNX2 RUNX3 regulates CDKN1A transcription Neddylation Transcriptional regulation of granulopoiesis FOXO-mediated transcription of cell cycle genes Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2 Regulation of pyruvate dehydrogenase (PDH) complex Signaling by Retinoic Acid Mitochondrial protein degradation PDH complex synthesizes acetyl-CoA from PYR	Drugs 1 Valproic acid Arsenic trioxide	Drugs 2 Pyruvic acid NADH	Diseases 1 Cervical cancer	Diseases 2 Pyruvate dehydrogenase complex deficiency; X-linked Leigh syndrome
Novel Novel	Symbols CDKN1A and RAI1	Name 1 cyclin dependent kinase inhibitor 1A	Name2 retinoic acid induced 1	Pathway 1 SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint TFAP2 (AP-2) family regulates transcription of cell cycle factors Transcriptional regulation by RUNX2 RUNX3 regulates CDKN1A transcription Neddylation Transcriptional regulation of granulopoiesis FOXO-mediated transcription of cell cycle genes Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2 Heme signaling Expression of BMAL (ARNTL), CLOCK, and NPAS2	Drugs 1 Valproic acid Arsenic trioxide	Drugs 2	Diseases 1 Cervical cancer	Diseases 2 Brachydacytly-mental retardation syndrome and Smith-Magenis syndrome
Novel Novel	Symbols CDKN1A and PDE4DIP	Name 1 cyclin dependent kinase inhibitor 1A	Name2 phosphodiesterase 4D interacting protein	Pathway 1 SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint TFAP2 (AP-2) family regulates transcription of cell cycle factors Transcriptional regulation by RUNX2 RUNX3 regulates CDKN1A transcription Neddylation Transcriptional regulation of granulopoiesis FOXO-mediated transcription of cell cycle genes Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2	Drugs 1 Valproic acid Arsenic trioxide	Drugs 2	Diseases 1 Cervical cancer	Diseases 2
Novel Novel	Symbols CDKN1A and FAF1	Name 1 cyclin dependent kinase inhibitor 1A	Name2 Fas associated factor 1	Pathway 1 SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint TFAP2 (AP-2) family regulates transcription of cell cycle factors Transcriptional regulation by RUNX2 RUNX3 regulates CDKN1A transcription Neddylation Transcriptional regulation of granulopoiesis FOXO-mediated transcription of cell cycle genes Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2	Drugs 1 Valproic acid Arsenic trioxide	Drugs 2	Diseases 1 Cervical cancer	Diseases 2
Novel Novel	Symbols CDKN1A and TNKS	Name 1 cyclin dependent kinase inhibitor 1A	Name2 tankyrase	Pathway 1 SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint TFAP2 (AP-2) family regulates transcription of cell cycle factors Transcriptional regulation by RUNX2 RUNX3 regulates CDKN1A transcription Neddylation Transcriptional regulation of granulopoiesis FOXO-mediated transcription of cell cycle genes Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2 TCF dependent signaling in response to WNT Degradation of AXIN XAV939 stabilizes AXIN Ub-specific processing proteases Regulation of PTEN stability and activity	Drugs 1 Valproic acid Arsenic trioxide	Drugs 2	Diseases 1 Cervical cancer	Diseases 2
Novel Novel	Symbols MCM2 and MCM6	Name 1 minichromosome maintenance complex component 2	Name2 minichromosome maintenance complex component 6	Pathway 1 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence	Pathway 2 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols MCM2 and TBP	Name 1 minichromosome maintenance complex component 2	Name2 TATA-box binding protein	Pathway 1 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence	Pathway 2 HIV Transcription Initiation RNA Polymerase II HIV Promoter Escape Transcription of the HIV genome SIRT1 negatively regulates rRNA expression NoRC negatively regulates rRNA expression B-WICH complex positively regulates rRNA expression RNA Polymerase II Pre-transcription Events Regulation of TP53 Activity through Phosphorylation RNA polymerase II transcribes snRNA genes RNA polymerase II transcribes snRNA genes RNA Polymerase I Transcription Initiation RNA Polymerase I Transcription Initiation RNA Polymerase I Promoter Escape RNA Polymerase II Promoter Escape RNA Polymerase II Transcription Pre-Initiation And Promoter Opening RNA Polymerase I Transcription Termination RNA Polymerase III Abortive And Retractive Initiation RNA Polymerase II Transcription Initiation RNA Polymerase II Transcription Initiation And Promoter Clearance RNA Polymerase III Transcription Initiation From Type 1 Promoter RNA Polymerase III Transcription Initiation From Type 1 Promoter RNA Polymerase III Transcription Initiation From Type 2 Promoter RNA Polymerase III Transcription Initiation From Type 2 Promoter RNA Polymerase III Transcription Initiation From Type 3 Promoter RNA Polymerase III Transcription Initiation From Type 3 Promoter Estrogen-dependent gene expression	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
Novel Novel	Symbols MCM2 and PTEN	Name 1 minichromosome maintenance complex component 2	Name2 phosphatase and tensin homolog	Pathway 1 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence	Pathway 2 Synthesis of PIPs at the plasma membrane Synthesis of IP3 and IP4 in the cytosol Negative regulation of the PI3K/AKT network Downstream TCR signaling TP53 Regulates Metabolic Genes PTEN Loss of Function in Cancer Ub-specific processing proteases Ovarian tumor domain proteases Regulation of PTEN mRNA translation Regulation of PTEN localization Regulation of PTEN stability and activity Transcriptional Regulation by MECP2	Drugs 1	Drugs 2 Phosphatidylethanolamine	Diseases 1	Diseases 2 Vulvar cancer Breast cancer Malignant melanoma Prostate cancer Hepatocellular carcinoma Small cell lung cancer Endometrial Cancer Glioma
Novel Novel	Symbols CDC25A and MAPK14	Name 1 cell division cycle 25A	Name2 mitogen-activated protein kinase 14	Pathway 1 Transcription of E2F targets under negative control by DREAM complex Polo-like kinase mediated events Activation of ATR in response to replication stress Ub-specific processing proteases Cyclin E associated events during G1/S transition Cyclin A/B1/B2 associated events during G2/M transition Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A Cyclin A:Cdk2-associated events at S phase entry Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	Pathway 2 NOD1/2 Signaling Pathway p38MAPK events p38MAPK events ERK/MAPK targets Activation of PPARGC1A (PGC-1alpha) by phosphorylation Oxidative Stress Induced Senescence ADP signalling through P2Y purinoceptor 1 Platelet sensitization by LDL VEGFA-VEGFR2 Pathway activated TAK1 mediates p38 MAPK activation Activation of the AP-1 family of transcription factors KSRP (KHSRP) binds and destabilizes mRNA Myogenesis Myogenesis RHO GTPases Activate NADPH Oxidases Neutrophil degranulation Regulation of TP53 Activity through Phosphorylation Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A CD163 mediating an anti-inflammatory response Regulation of MITF-M-dependent genes involved in pigmentation	Drugs 1	Drugs 2 Minocycline Dasatinib 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One Inhibitor of P38 Kinase 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea 3-(Benzyloxy)Pyridin-2-Amine l)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline Doramapimod 2-Chlorophenol 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole SB220025 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE Triazolopyridine KC706 Talmapimod VX-702 R-1487 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide Neflamapimod N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide PH-797804 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine SD-0006 N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO- 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE Fostamatinib	Diseases 1	Diseases 2
Novel Novel	Symbols CDC25A and HLA-C	Name 1 cell division cycle 25A	Name2 major histocompatibility complex, class I, C	Pathway 1 Transcription of E2F targets under negative control by DREAM complex Polo-like kinase mediated events Activation of ATR in response to replication stress Ub-specific processing proteases Cyclin E associated events during G1/S transition Cyclin A/B1/B2 associated events during G2/M transition Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A Cyclin A:Cdk2-associated events at S phase entry Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	Pathway 2 ER-Phagosome pathway ER-Phagosome pathway Endosomal/Vacuolar pathway Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell DAP12 interactions Neutrophil degranulation Interferon gamma signaling Interferon alpha/beta signaling SARS-CoV-2 activates/modulates innate and adaptive immune responses Antigen Presentation: Folding, assembly and peptide loading of class I MHC Antigen Presentation: Folding, assembly and peptide loading of class I MHC	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CDC25A and MTAP	Name 1 cell division cycle 25A	Name2 methylthioadenosine phosphorylase	Pathway 1 Transcription of E2F targets under negative control by DREAM complex Polo-like kinase mediated events Activation of ATR in response to replication stress Ub-specific processing proteases Cyclin E associated events during G1/S transition Cyclin A/B1/B2 associated events during G2/M transition Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A Cyclin A:Cdk2-associated events at S phase entry Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	Pathway 2 Methionine salvage pathway Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation	Drugs 1	Drugs 2 Adenine (2S,3S,4R,5S)-2-(4-Amino-4,5-dihydro-1H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-[(methylsulfanyl)methyl]-3,4-pyrrolidinediol Formycin 5'-S-methyl-5'-thioadenosine 5'-Deoxy-5'-(Methylthio)-Tubercidin	Diseases 1	Diseases 2
Novel Novel	Symbols CDC42 and HERC2	Name 1 cell division cycle 42	Name2 HECT and RLD domain containing E3 ubiquitin protein ligase 2	Pathway 1 GPVI-mediated activation cascade EGFR downregulation Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation CD28 dependent Vav1 pathway EPHB-mediated forward signaling EPHB-mediated forward signaling DCC mediated attractive signaling Inactivation of CDC42 and RAC1 VEGFA-VEGFR2 Pathway Myogenesis Myogenesis RHO GTPases activate KTN1 RHO GTPases activate IQGAPs RHO GTPases activate PAKs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate Formins RHO GTPases Activate Formins MAPK6/MAPK4 signaling Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation G beta:gamma signalling through CDC42 CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOQ GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RHOU GTPase cycle RAC3 GTPase cycle RHOV GTPase cycle FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis Factors involved in megakaryocyte development and platelet production	Pathway 2 SUMOylation of DNA damage response and repair proteins Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Nonhomologous End-Joining (NHEJ) Processing of DNA double-strand break ends G2/M DNA damage checkpoint Antigen processing: Ubiquitination & Proteasome degradation	Drugs 1 Aminophosphonic acid-guanylate ester Guanosine-5'-Diphosphate	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CDC42 and ARHGAP22	Name 1 cell division cycle 42	Name2 Rho GTPase activating protein 22	Pathway 1 GPVI-mediated activation cascade EGFR downregulation Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation CD28 dependent Vav1 pathway EPHB-mediated forward signaling EPHB-mediated forward signaling DCC mediated attractive signaling Inactivation of CDC42 and RAC1 VEGFA-VEGFR2 Pathway Myogenesis Myogenesis RHO GTPases activate KTN1 RHO GTPases activate IQGAPs RHO GTPases activate PAKs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate Formins RHO GTPases Activate Formins MAPK6/MAPK4 signaling Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation G beta:gamma signalling through CDC42 CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOQ GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RHOU GTPase cycle RAC3 GTPase cycle RHOV GTPase cycle FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis Factors involved in megakaryocyte development and platelet production	Pathway 2 RHOA GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle	Drugs 1 Aminophosphonic acid-guanylate ester Guanosine-5'-Diphosphate	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CTNNB1 and MEG3	Name 1 catenin beta 1	Name2 maternally expressed 3	Pathway 1 Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade TCF dependent signaling in response to WNT Formation of the beta-catenin:TCF transactivating complex Formation of the beta-catenin:TCF transactivating complex LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Apoptotic cleavage of cell adhesion proteins Deactivation of the beta-catenin transactivating complex Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Ca2+ pathway Adherens junctions interactions Binding of TCF/LEF:CTNNB1 to target gene promoters Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability Myogenesis Myogenesis Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated RHO GTPases activate IQGAPs Transcriptional Regulation by VENTX InlA-mediated entry of Listeria monocytogenes into host cells RUNX3 regulates WNT signaling Cardiogenesis Germ layer formation at gastrulation Regulation of CDH11 function Regulation of CDH11 function Regulation of CDH19 Expression and Function Regulation of CDH1 Function Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Formation of paraxial mesoderm Formation of axial mesoderm Formation of definitive endoderm Somitogenesis Regulation of MITF-M-dependent genes involved in pigmentation Regulation of MITF-M-dependent genes involved in cell cycle and proliferation Formation of the nephric duct CDH11 homotypic and heterotypic interactions Specification of the neural plate border High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Transcriptional and post-translational regulation of MITF-M expression and activity Regulation of PD-L1(CD274) transcription	Pathway 2	Drugs 1 Urea	Drugs 2	Diseases 1 Pilomatricoma; Epithelioma calcificans of Malherbe Gastric cancer Hepatocellular carcinoma Thyroid cancer Colorectal cancer Endometrial Cancer	Diseases 2
Novel	Symbols CTNNB1 and PFKFB3	Name 1 catenin beta 1	Name2 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Pathway 1 Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade TCF dependent signaling in response to WNT Formation of the beta-catenin:TCF transactivating complex Formation of the beta-catenin:TCF transactivating complex LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Apoptotic cleavage of cell adhesion proteins Deactivation of the beta-catenin transactivating complex Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Ca2+ pathway Adherens junctions interactions Binding of TCF/LEF:CTNNB1 to target gene promoters Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability Myogenesis Myogenesis Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated RHO GTPases activate IQGAPs Transcriptional Regulation by VENTX InlA-mediated entry of Listeria monocytogenes into host cells RUNX3 regulates WNT signaling Cardiogenesis Germ layer formation at gastrulation Regulation of CDH11 function Regulation of CDH11 function Regulation of CDH19 Expression and Function Regulation of CDH1 Function Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Formation of paraxial mesoderm Formation of axial mesoderm Formation of definitive endoderm Somitogenesis Regulation of MITF-M-dependent genes involved in pigmentation Regulation of MITF-M-dependent genes involved in cell cycle and proliferation Formation of the nephric duct CDH11 homotypic and heterotypic interactions Specification of the neural plate border High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Transcriptional and post-translational regulation of MITF-M expression and activity Regulation of PD-L1(CD274) transcription	Pathway 2 Regulation of glycolysis by fructose 2,6-bisphosphate metabolism	Drugs 1 Urea	Drugs 2	Diseases 1 Pilomatricoma; Epithelioma calcificans of Malherbe Gastric cancer Hepatocellular carcinoma Thyroid cancer Colorectal cancer Endometrial Cancer	Diseases 2
Novel	Symbols CTNNB1 and PTPRM	Name 1 catenin beta 1	Name2 protein tyrosine phosphatase receptor type M	Pathway 1 Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade TCF dependent signaling in response to WNT Formation of the beta-catenin:TCF transactivating complex Formation of the beta-catenin:TCF transactivating complex LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Apoptotic cleavage of cell adhesion proteins Deactivation of the beta-catenin transactivating complex Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Ca2+ pathway Adherens junctions interactions Binding of TCF/LEF:CTNNB1 to target gene promoters Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability Myogenesis Myogenesis Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated RHO GTPases activate IQGAPs Transcriptional Regulation by VENTX InlA-mediated entry of Listeria monocytogenes into host cells RUNX3 regulates WNT signaling Cardiogenesis Germ layer formation at gastrulation Regulation of CDH11 function Regulation of CDH11 function Regulation of CDH19 Expression and Function Regulation of CDH1 Function Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Formation of paraxial mesoderm Formation of axial mesoderm Formation of definitive endoderm Somitogenesis Regulation of MITF-M-dependent genes involved in pigmentation Regulation of MITF-M-dependent genes involved in cell cycle and proliferation Formation of the nephric duct CDH11 homotypic and heterotypic interactions Specification of the neural plate border High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Transcriptional and post-translational regulation of MITF-M expression and activity Regulation of PD-L1(CD274) transcription	Pathway 2	Drugs 1 Urea	Drugs 2	Diseases 1 Pilomatricoma; Epithelioma calcificans of Malherbe Gastric cancer Hepatocellular carcinoma Thyroid cancer Colorectal cancer Endometrial Cancer	Diseases 2
Novel	Symbols CTNNB1 and SALL1	Name 1 catenin beta 1	Name2 spalt like transcription factor 1	Pathway 1 Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade TCF dependent signaling in response to WNT Formation of the beta-catenin:TCF transactivating complex Formation of the beta-catenin:TCF transactivating complex LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Apoptotic cleavage of cell adhesion proteins Deactivation of the beta-catenin transactivating complex Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Ca2+ pathway Adherens junctions interactions Binding of TCF/LEF:CTNNB1 to target gene promoters Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability Myogenesis Myogenesis Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated RHO GTPases activate IQGAPs Transcriptional Regulation by VENTX InlA-mediated entry of Listeria monocytogenes into host cells RUNX3 regulates WNT signaling Cardiogenesis Germ layer formation at gastrulation Regulation of CDH11 function Regulation of CDH11 function Regulation of CDH19 Expression and Function Regulation of CDH1 Function Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Formation of paraxial mesoderm Formation of axial mesoderm Formation of definitive endoderm Somitogenesis Regulation of MITF-M-dependent genes involved in pigmentation Regulation of MITF-M-dependent genes involved in cell cycle and proliferation Formation of the nephric duct CDH11 homotypic and heterotypic interactions Specification of the neural plate border High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Transcriptional and post-translational regulation of MITF-M expression and activity Regulation of PD-L1(CD274) transcription	Pathway 2 POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation Formation of the ureteric bud	Drugs 1 Urea	Drugs 2	Diseases 1 Pilomatricoma; Epithelioma calcificans of Malherbe Gastric cancer Hepatocellular carcinoma Thyroid cancer Colorectal cancer Endometrial Cancer	Diseases 2 Townes-Brocks syndrome
Novel	Symbols CUX1 and EHMT2	Name 1 cut like homeobox 1	Name2 euchromatic histone lysine methyltransferase 2	Pathway 1 Signaling by cytosolic FGFR1 fusion mutants Signaling by FGFR1 in disease Intra-Golgi traffic	Pathway 2 Senescence-Associated Secretory Phenotype (SASP) PKMTs methylate histone lysines ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression Regulation of TP53 Activity through Methylation RNA Polymerase I Transcription Initiation Transcriptional Regulation by VENTX Transcriptional Regulation by E2F6 Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CDKN1A and CSAD	Name 1 cyclin dependent kinase inhibitor 1A	Name2 cysteine sulfinic acid decarboxylase	Pathway 1 SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint TFAP2 (AP-2) family regulates transcription of cell cycle factors Transcriptional regulation by RUNX2 RUNX3 regulates CDKN1A transcription Neddylation Transcriptional regulation of granulopoiesis FOXO-mediated transcription of cell cycle genes Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2 Degradation of cysteine and homocysteine	Drugs 1 Valproic acid Arsenic trioxide	Drugs 2 Pyridoxal phosphate Cysteine	Diseases 1 Cervical cancer	Diseases 2
Novel	Symbols CDKN1A and F13A1	Name 1 cyclin dependent kinase inhibitor 1A	Name2 coagulation factor XIII A chain	Pathway 1 SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint TFAP2 (AP-2) family regulates transcription of cell cycle factors Transcriptional regulation by RUNX2 RUNX3 regulates CDKN1A transcription Neddylation Transcriptional regulation of granulopoiesis FOXO-mediated transcription of cell cycle genes Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2 Platelet degranulation Common Pathway of Fibrin Clot Formation Interleukin-4 and Interleukin-13 signaling	Drugs 1 Valproic acid Arsenic trioxide	Drugs 2 N-Acetyl-Serine Thrombin Prothrombin Human thrombin Anti-inhibitor coagulant complex	Diseases 1 Cervical cancer	Diseases 2 Factor XIII deficiency
Novel	Symbols CDKN1A and PDHB	Name 1 cyclin dependent kinase inhibitor 1A	Name2 pyruvate dehydrogenase E1 subunit beta	Pathway 1 SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint TFAP2 (AP-2) family regulates transcription of cell cycle factors Transcriptional regulation by RUNX2 RUNX3 regulates CDKN1A transcription Neddylation Transcriptional regulation of granulopoiesis FOXO-mediated transcription of cell cycle genes Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2 Regulation of pyruvate dehydrogenase (PDH) complex Signaling by Retinoic Acid Mitochondrial protein degradation PDH complex synthesizes acetyl-CoA from PYR	Drugs 1 Valproic acid Arsenic trioxide	Drugs 2 Pyruvic acid NADH	Diseases 1 Cervical cancer	Diseases 2 Pyruvate dehydrogenase complex deficiency; X-linked Leigh syndrome
Novel	Symbols CDKN1A and RAI1	Name 1 cyclin dependent kinase inhibitor 1A	Name2 retinoic acid induced 1	Pathway 1 SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint TFAP2 (AP-2) family regulates transcription of cell cycle factors Transcriptional regulation by RUNX2 RUNX3 regulates CDKN1A transcription Neddylation Transcriptional regulation of granulopoiesis FOXO-mediated transcription of cell cycle genes Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2 Heme signaling Expression of BMAL (ARNTL), CLOCK, and NPAS2	Drugs 1 Valproic acid Arsenic trioxide	Drugs 2	Diseases 1 Cervical cancer	Diseases 2 Brachydacytly-mental retardation syndrome and Smith-Magenis syndrome
Novel	Symbols CDKN1A and PDE4DIP	Name 1 cyclin dependent kinase inhibitor 1A	Name2 phosphodiesterase 4D interacting protein	Pathway 1 SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint TFAP2 (AP-2) family regulates transcription of cell cycle factors Transcriptional regulation by RUNX2 RUNX3 regulates CDKN1A transcription Neddylation Transcriptional regulation of granulopoiesis FOXO-mediated transcription of cell cycle genes Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2	Drugs 1 Valproic acid Arsenic trioxide	Drugs 2	Diseases 1 Cervical cancer	Diseases 2
Novel	Symbols CDKN1A and FAF1	Name 1 cyclin dependent kinase inhibitor 1A	Name2 Fas associated factor 1	Pathway 1 SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint TFAP2 (AP-2) family regulates transcription of cell cycle factors Transcriptional regulation by RUNX2 RUNX3 regulates CDKN1A transcription Neddylation Transcriptional regulation of granulopoiesis FOXO-mediated transcription of cell cycle genes Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2	Drugs 1 Valproic acid Arsenic trioxide	Drugs 2	Diseases 1 Cervical cancer	Diseases 2
Novel	Symbols CDKN1A and TNKS	Name 1 cyclin dependent kinase inhibitor 1A	Name2 tankyrase	Pathway 1 SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint TFAP2 (AP-2) family regulates transcription of cell cycle factors Transcriptional regulation by RUNX2 RUNX3 regulates CDKN1A transcription Neddylation Transcriptional regulation of granulopoiesis FOXO-mediated transcription of cell cycle genes Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2 TCF dependent signaling in response to WNT Degradation of AXIN XAV939 stabilizes AXIN Ub-specific processing proteases Regulation of PTEN stability and activity	Drugs 1 Valproic acid Arsenic trioxide	Drugs 2	Diseases 1 Cervical cancer	Diseases 2
Novel	Symbols MCM2 and MCM6	Name 1 minichromosome maintenance complex component 2	Name2 minichromosome maintenance complex component 6	Pathway 1 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence	Pathway 2 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols MCM2 and TBP	Name 1 minichromosome maintenance complex component 2	Name2 TATA-box binding protein	Pathway 1 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence	Pathway 2 HIV Transcription Initiation RNA Polymerase II HIV Promoter Escape Transcription of the HIV genome SIRT1 negatively regulates rRNA expression NoRC negatively regulates rRNA expression B-WICH complex positively regulates rRNA expression RNA Polymerase II Pre-transcription Events Regulation of TP53 Activity through Phosphorylation RNA polymerase II transcribes snRNA genes RNA polymerase II transcribes snRNA genes RNA Polymerase I Transcription Initiation RNA Polymerase I Transcription Initiation RNA Polymerase I Promoter Escape RNA Polymerase II Promoter Escape RNA Polymerase II Transcription Pre-Initiation And Promoter Opening RNA Polymerase I Transcription Termination RNA Polymerase III Abortive And Retractive Initiation RNA Polymerase II Transcription Initiation RNA Polymerase II Transcription Initiation And Promoter Clearance RNA Polymerase III Transcription Initiation From Type 1 Promoter RNA Polymerase III Transcription Initiation From Type 1 Promoter RNA Polymerase III Transcription Initiation From Type 2 Promoter RNA Polymerase III Transcription Initiation From Type 2 Promoter RNA Polymerase III Transcription Initiation From Type 3 Promoter RNA Polymerase III Transcription Initiation From Type 3 Promoter Estrogen-dependent gene expression	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
Novel	Symbols MCM2 and PTEN	Name 1 minichromosome maintenance complex component 2	Name2 phosphatase and tensin homolog	Pathway 1 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence	Pathway 2 Synthesis of PIPs at the plasma membrane Synthesis of IP3 and IP4 in the cytosol Negative regulation of the PI3K/AKT network Downstream TCR signaling TP53 Regulates Metabolic Genes PTEN Loss of Function in Cancer Ub-specific processing proteases Ovarian tumor domain proteases Regulation of PTEN mRNA translation Regulation of PTEN localization Regulation of PTEN stability and activity Transcriptional Regulation by MECP2	Drugs 1	Drugs 2 Phosphatidylethanolamine	Diseases 1	Diseases 2 Vulvar cancer Breast cancer Malignant melanoma Prostate cancer Hepatocellular carcinoma Small cell lung cancer Endometrial Cancer Glioma
Novel	Symbols CDC25A and MAPK14	Name 1 cell division cycle 25A	Name2 mitogen-activated protein kinase 14	Pathway 1 Transcription of E2F targets under negative control by DREAM complex Polo-like kinase mediated events Activation of ATR in response to replication stress Ub-specific processing proteases Cyclin E associated events during G1/S transition Cyclin A/B1/B2 associated events during G2/M transition Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A Cyclin A:Cdk2-associated events at S phase entry Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	Pathway 2 NOD1/2 Signaling Pathway p38MAPK events p38MAPK events ERK/MAPK targets Activation of PPARGC1A (PGC-1alpha) by phosphorylation Oxidative Stress Induced Senescence ADP signalling through P2Y purinoceptor 1 Platelet sensitization by LDL VEGFA-VEGFR2 Pathway activated TAK1 mediates p38 MAPK activation Activation of the AP-1 family of transcription factors KSRP (KHSRP) binds and destabilizes mRNA Myogenesis Myogenesis RHO GTPases Activate NADPH Oxidases Neutrophil degranulation Regulation of TP53 Activity through Phosphorylation Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A CD163 mediating an anti-inflammatory response Regulation of MITF-M-dependent genes involved in pigmentation	Drugs 1	Drugs 2 Minocycline Dasatinib 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One Inhibitor of P38 Kinase 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea 3-(Benzyloxy)Pyridin-2-Amine l)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline Doramapimod 2-Chlorophenol 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole SB220025 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE Triazolopyridine KC706 Talmapimod VX-702 R-1487 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide Neflamapimod N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide PH-797804 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine SD-0006 N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO- 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE Fostamatinib	Diseases 1	Diseases 2
Novel	Symbols CDC25A and HLA-C	Name 1 cell division cycle 25A	Name2 major histocompatibility complex, class I, C	Pathway 1 Transcription of E2F targets under negative control by DREAM complex Polo-like kinase mediated events Activation of ATR in response to replication stress Ub-specific processing proteases Cyclin E associated events during G1/S transition Cyclin A/B1/B2 associated events during G2/M transition Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A Cyclin A:Cdk2-associated events at S phase entry Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	Pathway 2 ER-Phagosome pathway ER-Phagosome pathway Endosomal/Vacuolar pathway Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell DAP12 interactions Neutrophil degranulation Interferon gamma signaling Interferon alpha/beta signaling SARS-CoV-2 activates/modulates innate and adaptive immune responses Antigen Presentation: Folding, assembly and peptide loading of class I MHC Antigen Presentation: Folding, assembly and peptide loading of class I MHC	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CDC25A and MTAP	Name 1 cell division cycle 25A	Name2 methylthioadenosine phosphorylase	Pathway 1 Transcription of E2F targets under negative control by DREAM complex Polo-like kinase mediated events Activation of ATR in response to replication stress Ub-specific processing proteases Cyclin E associated events during G1/S transition Cyclin A/B1/B2 associated events during G2/M transition Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A Cyclin A:Cdk2-associated events at S phase entry Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	Pathway 2 Methionine salvage pathway Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation	Drugs 1	Drugs 2 Adenine (2S,3S,4R,5S)-2-(4-Amino-4,5-dihydro-1H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-[(methylsulfanyl)methyl]-3,4-pyrrolidinediol Formycin 5'-S-methyl-5'-thioadenosine 5'-Deoxy-5'-(Methylthio)-Tubercidin	Diseases 1	Diseases 2
Novel	Symbols CDC42 and HERC2	Name 1 cell division cycle 42	Name2 HECT and RLD domain containing E3 ubiquitin protein ligase 2	Pathway 1 GPVI-mediated activation cascade EGFR downregulation Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation CD28 dependent Vav1 pathway EPHB-mediated forward signaling EPHB-mediated forward signaling DCC mediated attractive signaling Inactivation of CDC42 and RAC1 VEGFA-VEGFR2 Pathway Myogenesis Myogenesis RHO GTPases activate KTN1 RHO GTPases activate IQGAPs RHO GTPases activate PAKs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate Formins RHO GTPases Activate Formins MAPK6/MAPK4 signaling Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation G beta:gamma signalling through CDC42 CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOQ GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RHOU GTPase cycle RAC3 GTPase cycle RHOV GTPase cycle FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis Factors involved in megakaryocyte development and platelet production	Pathway 2 SUMOylation of DNA damage response and repair proteins Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Nonhomologous End-Joining (NHEJ) Processing of DNA double-strand break ends G2/M DNA damage checkpoint Antigen processing: Ubiquitination & Proteasome degradation	Drugs 1 Aminophosphonic acid-guanylate ester Guanosine-5'-Diphosphate	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CDC42 and ARHGAP22	Name 1 cell division cycle 42	Name2 Rho GTPase activating protein 22	Pathway 1 GPVI-mediated activation cascade EGFR downregulation Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation CD28 dependent Vav1 pathway EPHB-mediated forward signaling EPHB-mediated forward signaling DCC mediated attractive signaling Inactivation of CDC42 and RAC1 VEGFA-VEGFR2 Pathway Myogenesis Myogenesis RHO GTPases activate KTN1 RHO GTPases activate IQGAPs RHO GTPases activate PAKs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate Formins RHO GTPases Activate Formins MAPK6/MAPK4 signaling Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation G beta:gamma signalling through CDC42 CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOQ GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RHOU GTPase cycle RAC3 GTPase cycle RHOV GTPase cycle FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis Factors involved in megakaryocyte development and platelet production	Pathway 2 RHOA GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle	Drugs 1 Aminophosphonic acid-guanylate ester Guanosine-5'-Diphosphate	Drugs 2	Diseases 1	Diseases 2

Page 19 out of 58 pages

Search Results : Diabetes